Tonix Pharmaceuticals (TNXP) announced that Tonix Medicines, Inc., its commercial subsidiary, launched the Move Fibro Forward campaign to bring awareness and support to individuals impacted by fibromyalgia, a debilitating condition with no new FDA-approved treatments in over 15 years. “Millions of individuals impacted by fibromyalgia have suffered in silence for far too long,” said Thomas Englese, President of Tonix Medicines, Inc. “We believe that demonstrating our knowledge of, and compassion for, their condition and validation of their experience is an important step toward meaningful progress. This campaign is a reflection of our commitment to the community-both today and in the future.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharma Plans Sales Force for TNX-102 SL
- Tonix Pharma Unveils Promising TNX-801 Vaccine Findings
- Tonix Pharmaceuticals to present new data on mpox and smallpox vaccine candidate
- Tonix Pharma Publishes Phase 3 Trial Results
- Tonix Pharmaceuticals publishes results from RESILIENT trial in Pain Medicine